Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Int J Pharm ; 660: 124322, 2024 Jul 20.
Artigo em Inglês | MEDLINE | ID: mdl-38866082

RESUMO

Podocytes, cells of the glomerular filtration barrier, play a crucial role in kidney diseases and are gaining attention as potential targets for new therapies. Brain-Derived Neurotrophic Factor (BDNF) has shown promising results in repairing podocyte damage, but its efficacy via parenteral administration is limited by a short half-life. Low temperature sensitive liposomes (LTSL) are a promising tool for targeted BDNF delivery, preserving its activity after encapsulation. This study aimed to improve LTSL design for efficient BDNF encapsulation and targeted release to podocytes, while maintaining stability and biological activity, and exploiting the conjugation of targeting peptides. While cyclic RGD (cRGD) was used for targeting endothelial cells in vitro, a homing peptide (HITSLLS) was conjugated for more specific uptake by glomerular endothelial cells in vivo. BDNF-loaded LTSL successfully repaired cytoskeleton damage in podocytes and reduced albumin permeability in a glomerular co-culture model. cRGD conjugation enhanced endothelial cell targeting and uptake, highlighting an improved therapeutic effect when BDNF release was induced by thermoresponsive liposomal degradation. In vivo, targeted LTSL showed evidence of accumulation in the kidneys, and their BDNF delivery decreased proteinuria and ameliorated kidney histology. These findings highlight the potential of BDNF-LTSL formulations in restoring podocyte function and treating glomerular diseases.


Assuntos
Fator Neurotrófico Derivado do Encéfalo , Sistemas de Liberação de Medicamentos , Lipossomos , Podócitos , Podócitos/efeitos dos fármacos , Podócitos/metabolismo , Animais , Fator Neurotrófico Derivado do Encéfalo/administração & dosagem , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/metabolismo , Humanos , Camundongos , Masculino , Temperatura Baixa , Técnicas de Cocultura , Peptídeos Cíclicos/administração & dosagem , Peptídeos Cíclicos/química , Rim/efeitos dos fármacos , Rim/metabolismo , Camundongos Endogâmicos C57BL , Liberação Controlada de Fármacos
2.
Toxicol Lett ; 301: 157-167, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30476537

RESUMO

Gadolinium deposition in tissue is linked to nephrogenic systemic fibrosis (NSF): a rare disorder occurring in patients with severe chronic kidney disease and associated with administration of Gd-based contrast agents (GBCAs) for Magnetic Resonance Imaging (MRI). It is suggested that the GBCAs prolonged permanence in blood in these patients may result in a Gd precipitation in peripheral or central organs, where it initiates a fibrotic process. In this study we investigated new sites of retention/precipitation of Gd in a mouse model of renal disease (5/6 nephrectomy) receiving two doses (closely after each other) of a linear GBCA. Two commercial GBCAs (Omniscan® and Magnevist®) were administered at doses slightly higher than those used in clinical practice (0.7 mmol/kg body weight, each). The animals were sacrificed one month after the last administration and the explanted organs (kidney, liver, femur, dorsal skin, teeth) were analysed by X-ray fluorescence (XRF) at two synchrotron facilities. The XRF analysis with a millimetre-sized beam at the SYRMEP beamline (Elettra, Italy) produced no detectable levels of Gd in the examined tissues, with the notable exception of the incisors of the nephrectomised mice. The XRF analyses at sub-micron resolution performed at ID21 (ESRF, France) allowed to clearly localize Gd in the periodontal ligaments of teeth both from Omniscan® and Magnevist® treated nephrectomised mice. The latter results were further confirmed by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). The study prompts that prolonged permanence of GBCAs in blood may result in Gd retention in this particular muscular tissue, opening possibilities for diagnostic applications at this level when investigating Gd-related toxicities.


Assuntos
Meios de Contraste/farmacocinética , Gadolínio/farmacocinética , Ligamento Periodontal/efeitos dos fármacos , Animais , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Feminino , Gadolínio DTPA/farmacocinética , Imageamento por Ressonância Magnética , Camundongos , Dermopatia Fibrosante Nefrogênica/induzido quimicamente , Dermopatia Fibrosante Nefrogênica/patologia , Ligamento Periodontal/metabolismo , Insuficiência Renal/induzido quimicamente , Insuficiência Renal/patologia , Distribuição Tecidual
3.
J Cardiovasc Pharmacol ; 44(3): 401-6, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15475840

RESUMO

Besides generating renal damage, hypertension plays an important role in the progression of diabetic nephropathy. The fructose-fed rat is a well-established model both of high blood pressure and renal impairment, which is similar to diabetic nephropathy. To clarify the relationship between hypertension, glucose metabolism, and kidney remodeling, we investigated the renal level of Glut 1 and Glut 5, their relation to fibrosis and the effects of an antihypertensive drug on renal damage. Twenty-four male WK rats were divided into three groups: 8 animals received a fructose-enriched diet, 8 a control diet, and 8 animals a high-fructose diet plus amlodipine (5 mg/Kg). After six weeks of treatment, we observed a significant increase in Glut 5, fibronectin, and sorbitol in fructose-fed rats compared with control and amlodipine-treated animals; there was a positive correlation between Glut 5 and fibronectin levels (r = 0.63). Glut 1 levels were similar in all three groups, whereas collagen IV was higher in fructose-fed rats; amlodipine prevented the increase of collagen IV and sorbitol. Collagen I was statistically higher in the fructose group than in the other two groups. Therefore, prolonged fructose feeding results in renal fibrosis via polyol pathway overactivity that can be prevented by means of an antihypertensive drug.


Assuntos
Anlodipino/uso terapêutico , Hipertensão/tratamento farmacológico , Nefropatias/tratamento farmacológico , Polímeros/metabolismo , Administração Oral , Anlodipino/administração & dosagem , Anlodipino/farmacocinética , Animais , Glicemia , Pressão Sanguínea/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Colágeno Tipo I/química , Colágeno Tipo I/metabolismo , Colágeno Tipo IV/antagonistas & inibidores , Colágeno Tipo IV/química , Colágeno Tipo IV/metabolismo , Dieta , Modelos Animais de Doenças , Fibronectinas/antagonistas & inibidores , Fibronectinas/química , Fibronectinas/metabolismo , Frutose/administração & dosagem , Frutose/efeitos adversos , Transportador de Glucose Tipo 1 , Transportador de Glucose Tipo 5 , Hipertensão/induzido quimicamente , Hipertensão/complicações , Imuno-Histoquímica/métodos , Insulina/sangue , Rim/química , Rim/efeitos dos fármacos , Rim/metabolismo , Nefropatias/induzido quimicamente , Nefropatias/complicações , Masculino , Proteínas de Transporte de Monossacarídeos/química , Proteínas de Transporte de Monossacarídeos/metabolismo , Tamanho do Órgão/efeitos dos fármacos , Polímeros/efeitos adversos , Ratos , Ratos Endogâmicos WKY , Sorbitol/antagonistas & inibidores , Sorbitol/química , Sorbitol/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA